798,482 Shares in Standard BioTools Inc. $LAB Acquired by Nuveen LLC

Key Points

• Nuveen LLC acquired a new stake in Standard BioTools Inc., buying 798,482 shares valued at approximately $862,000, representing about 0.21% of the company's total shares outstanding.
• Institutional investors collectively own 53.74% of Standard BioTools stock, with notable increases in stakes from firms like Pacific Capital Partners and GSA Capital Partners.
• Standard BioTools has faced mixed analyst ratings, with TD Cowen downgrading the stock from a "buy" to a "hold," setting a price target of $1.55.

Nuveen LLC purchased a new stake in Standard BioTools Inc. (NASDAQ:LAB - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 798,482 shares of the company's stock, valued at approximately $862,000. Nuveen LLC owned about 0.21% of Standard BioTools as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in LAB. Wells Fargo & Company MN boosted its holdings in Standard BioTools by 29.1% in the fourth quarter. Wells Fargo & Company MN now owns 181,256 shares of the company's stock valued at $317,000 after purchasing an additional 40,894 shares during the last quarter. MetLife Investment Management LLC boosted its holdings in Standard BioTools by 27.9% in the fourth quarter. MetLife Investment Management LLC now owns 183,382 shares of the company's stock valued at $321,000 after purchasing an additional 40,057 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Standard BioTools by 10.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 181,468 shares of the company's stock valued at $318,000 after purchasing an additional 16,475 shares during the last quarter. Aquatic Capital Management LLC purchased a new stake in Standard BioTools in the fourth quarter valued at $45,000. Finally, Northern Trust Corp boosted its holdings in Standard BioTools by 9.3% in the fourth quarter. Northern Trust Corp now owns 2,875,160 shares of the company's stock valued at $5,032,000 after purchasing an additional 243,522 shares during the last quarter. 53.74% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Standard BioTools

In other news, Director Casdin Partners Master Fund, L purchased 250,000 shares of the company's stock in a transaction dated Wednesday, September 3rd. The stock was acquired at an average price of $1.27 per share, with a total value of $317,500.00. Following the purchase, the director directly owned 60,525,000 shares in the company, valued at approximately $76,866,750. This represents a 0.41% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Over the last three months, insiders have purchased 1,133,220 shares of company stock valued at $1,417,446. Corporate insiders own 23.16% of the company's stock.

Standard BioTools Trading Up 0.8%

LAB stock traded up $0.01 during mid-day trading on Friday, reaching $1.30. The company's stock had a trading volume of 1,393,420 shares, compared to its average volume of 1,193,529. The company's 50 day moving average is $1.30 and its two-hundred day moving average is $1.18. Standard BioTools Inc. has a fifty-two week low of $0.92 and a fifty-two week high of $2.32. The stock has a market cap of $496.59 million, a PE ratio of -4.06 and a beta of 1.29.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. TD Cowen downgraded shares of Standard BioTools from a "buy" rating to a "hold" rating and set a $1.55 price objective for the company. in a research report on Wednesday, August 13th. Cowen downgraded shares of Standard BioTools from a "buy" rating to a "hold" rating in a research report on Wednesday, August 13th. Finally, Wall Street Zen upgraded shares of Standard BioTools from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. Three analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, Standard BioTools presently has an average rating of "Hold" and a consensus price target of $1.55.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.